EPO published patent application EP3633378A1 for a Chromogranin A immunoassay with applications in neuroendocrine tumour and prostate cancer diagnostics. The applicants are Cézanne S.A.S. with inventors Caruhel, Rigault, and Guérin. The patent covers IPC classifications G01N 33/577, C07K 16/18, and C07K 16/30. The application is designated for all EU member states plus Switzerland, Norway, Turkey, and other European countries.\n\nThis is a patent publication rather than a regulatory requirement. No compliance actions are required from pharmaceutical or diagnostic companies. Entities developing similar immunoassays should monitor this application for potential IP implications and consider conducting freedom-to-operate analyses if commercializing related diagnostic products in the designated states.